Trabectedin Plus Pegylated Liposomal Doxorubicin in Recurrent Ovarian Cancer

• Published in: Journal of clinical oncology Vol. 28; no. 19; pp. 3107 - 3114
• Main Authors: Monk, Bradley J., Herzog, Thomas J., Kaye, Stanley B., Krasner, Carolyn N., Vermorken, Jan B., Muggia, Franco M., Pujade-Lauraine, Eric, Lisyanskaya, Alla S., Makhson, Anatoly N., Rolski, Janusz, Gorbounova, Vera A., Ghatage, Prafull, Bidzinski, Mariusz, Shen, Keng, Ngan, Hextan Yuen-Sheung, Vergote, Ignace B., Nam, Joo-Hyun, Park, Youn Choi, Lebedinsky, Claudia A., Poveda, Andrés M.
• Format: Journal Article
• Language: English
• Published: United States American Society of Clinical Oncology 01.07.2010
• Subjects: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Dioxoles - administration & dosage; Dioxoles - adverse effects; Doxorubicin - administration & dosage; Doxorubicin - adverse effects; Doxorubicin - analogs & derivatives; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Leukopenia - chemically induced; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Neutropenia - chemically induced; Ovarian Neoplasms - drug therapy; Ovarian Neoplasms - pathology; Polyethylene Glycols - administration & dosage; Polyethylene Glycols - adverse effects; Stomatitis - chemically induced; Tetrahydroisoquinolines - administration & dosage; Tetrahydroisoquinolines - adverse effects; Treatment Outcome

The objective of this study was to compare the efficacy and safety of trabectedin plus pegylated liposomal doxorubicin (PLD) with that of PLD alone in women with recurrent ovarian cancer after failure of first-line, platinum-based chemotherapy. Women > or = 18 years, stratified by performance sta...